- Home
- GALT vs YI Comparison
GALT vs YI Comparison
Compare GALT & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- YI
- Stock Information
- Founded
- GALT 2000
- YI 2010
- Country
- GALT United States
- YI China
- Employees
- GALT N/A
- YI N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- YI Retail-Drug Stores and Proprietary Stores
- Sector
- GALT Health Care
- YI Consumer Staples
- Exchange
- GALT Nasdaq
- YI Nasdaq
- Market Cap
- GALT 83.5M
- YI 70.0M
- IPO Year
- GALT N/A
- YI N/A
- Fundamental
- Price
- GALT $2.60
- YI $8.00
- Analyst Decision
- GALT Buy
- YI
- Analyst Count
- GALT 2
- YI 0
- Target Price
- GALT $6.00
- YI N/A
- AVG Volume (30 Days)
- GALT 1.2M
- YI 11.5K
- Earning Date
- GALT 08-12-2025
- YI 06-19-2025
- Dividend Yield
- GALT N/A
- YI N/A
- EPS Growth
- GALT N/A
- YI N/A
- EPS
- GALT N/A
- YI N/A
- Revenue
- GALT N/A
- YI $1,984,717,013.00
- Revenue This Year
- GALT N/A
- YI N/A
- Revenue Next Year
- GALT N/A
- YI N/A
- P/E Ratio
- GALT N/A
- YI N/A
- Revenue Growth
- GALT N/A
- YI N/A
- 52 Week Low
- GALT $0.73
- YI $4.15
- 52 Week High
- GALT $3.90
- YI $12.90
- Technical
- Relative Strength Index (RSI)
- GALT 70.66
- YI 49.11
- Support Level
- GALT $1.28
- YI $7.40
- Resistance Level
- GALT $1.36
- YI $8.69
- Average True Range (ATR)
- GALT 0.33
- YI 0.41
- MACD
- GALT 0.18
- YI -0.02
- Stochastic Oscillator
- GALT 52.40
- YI 46.51
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.